secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elevation Oncology, Inc. (—)
CIK:        0001783032
Form:       8-K
Filed at:   2023-03-03T23:59:59+00:00
Accession:  0001558370-23-002780
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elevation Oncology amends bylaws for universal proxy rules and DGCL updates
---------------------------------------------------------------------------

- Board approved amended bylaws effective March 3, 2023, to comply with SEC universal proxy rules.
- New provisions require stockholders to certify compliance with Rule 14a-19 and provide evidence 5 business days before meeting.
- Advance notice bylaws updated: additional disclosures, nominee interview requirement, and limit on nominees to board seats.
- Changes align with recent Delaware law amendments on electronic notice, adjournment, and stockholder lists.
- Added emergency bylaw provision for director quorum during crises; other ministerial and clarifying updates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783032/000155837023002780/0001558370-23-002780-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783032/000155837023002780/elev-20230303x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-002780

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer